YOLFTbeta
BIOBIJOU Co.,Ltd.

BIOBIJOU Co.,Ltd.

489460 · KQ · Healthcare / Medical Instruments & Supplies

15,340.00KRW+200.00 (+1.32%)

Price History

Full chart

Market Stats

Previous Close15,140.00
Open15,150.00
Day Range15,000.00 – 15,550.00
52-Week Range5,610.00 – 16,098.77
Volume147.99K
Market Cap173.46B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.87%
50-Day Avg11,110.60
200-Day Avg9,684.40

About

BIOBIJOU Co.,Ltd. engages in the research, development, manufacturing, and sale of skin booster and filler products in South Korea. It offers cosmetic products which includes skin boosters which is used in treatment to improve skin condition using microneedle therapy system; medical devices include hyaluronic acid dermal fillers under the COLENA PREMIUM and CANDORLOV brand name; and pharmaceuticals, such as include botulinum toxin. It also exports its products to Iraq, the Dominican Republic, Turkey, China, Vietnam, Hong Kong, Russia, Malaysia, the United Kingdom, CIS, and Colombia. The company was founded in 2018 and is based in Hanam-si, South Korea. BIOBIJOU Co.,Ltd. is a subsidiary of CHUNGDAMGLOBAL Co., Ltd.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Joonho Yang
  • HeadquartersA-1516, Hanam Techno Valley, Hanam-si, South Korea, Korea
  • Websitehttps://www.biobijou.co.kr

Leadership

  • Mr. Joonho YangCEO & Representative Chairman · b. 1970
  • Mr. Yeong-Je KimCFO, COO & Inside Director · b. 1983
  • SeongSeo ParkDirector of Research Institute (CTO) · b. 1979
  • HoGeol NamGlobal Sales Director, CMO & Inside Director · b. 1988
  • GwangWoo ParkHead of Production Quality Headquarter · b. 1970

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue21.06B17.13B29.63B28.49B
Growth (%)--18.68%+72.99%-3.86%
Cost of Revenue15.62B8.86B14.78B12.57B
Gross Profit5.44B8.27B14.85B15.92B
Gross Margin25.84%48.30%50.12%55.88%
Operating Expense1.80B3.11B5.62B11.69B
Operating Income3.64B5.16B9.23B4.23B
Operating Margin17.28%30.15%31.14%14.84%
EBITDA2.10B5.41B10.12B5.81B
EBITDA Margin9.98%31.58%34.16%20.40%
Net Income692.82M3.31B7.19B4.15B
Net Income Margin3.29%19.32%24.26%14.57%
R&D401.95M632.70M1.21B841.97M
R&D as % of Total Revenue1.91%3.69%4.09%2.96%
Interest Expense466.56M594.63M444.24M38.20M
Interest Expense % of Total Revenue2.21%3.47%1.50%0.13%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets21.71B27.93B37.79B63.75B
Total Liabilities13.84B16.42B6.84B1.77B
Total Equity7.87B11.51B30.95B61.96B
Cash7.96B1.63B8.39B11.64B
Net Debt-13.07B--

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.10B4.07B558.34M-2.77B
Capital Expenditure398.67M77.56M177.86M786.06M
Free Cash Flow1.70B4.00B380.48M-3.56B
FCF to OCF81.03%98.10%68.15%128.37%

Earnings

Report DateJun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----
EPS Actual38.20162.06-90.33188.90166.45
Surprise-----
Timing-----

Key Statistics & Ratios

Market Cap173.46B
Enterprise Value160.80B
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.07
Price / Book2.75
Revenue (TTM)28.56B
Gross Profit (TTM)15.97B
EBITDA5.78B
Profit Margin22.83%
Operating Margin27.35%
Return on Equity10.40%
Return on Assets4.72%
Shares Outstanding15.04M
Shares Float3.55M
Dividend Yield0.87%
Dividend Rate100.00
Payout Ratio23.42%

Dividends

20251×
100.00Dec 29, 2025